Abstract Library

#2068 Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Hernando-Cubero J

Authors: Hernando-Cubero J, Manzano J, Benavent M, Lopez C, Teulé R,

Keywords: Durvalumab, Tremelimumab, Neuroendocrine, Immunotherapy,

#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan

Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kasajima A

Authors: Kasajima A, Tachibana T, Ishida H, Yazdani S, Konukiewitz B,

Keywords: NET G3, GEP-NEN, GI-NET,

#1323 Expression of Oncofetal Protein IMP3 in Lymph Node Metastases of Small Intestine Neuroendocrine Neoplasms: A New Predictor of Recurrence

Introduction: Small intestine neuroendocrine neoplasm (SINENs) are heterogeneous neoplasms arising from endocrine cells of the intestinal mucosa. Ki67 is the main determinant of prognosis in NENs. However, the research for new prognostic makers represent a key-point. The oncofetal protein IMP3 plays a role in cell growth and its expression has a prognostic value in lung neoplasms.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Cavalcoli F

Authors: Massironi S, Del Gobbo A, Cavalcoli F, Fiori S, Conte D,

Keywords: IMP3, intestinal NENs,

#1215 Describing NENs: Just Clinical/Biologic Features or Actual Prognostic Factors?

Introduction: Neuroendocrine neoplasias (NENs) are a rare group of diseases, with several possible locations and manifestations, often representing a challenging diagnosis. It is essential to improve tools that accurately predict aggressiveness and prognosis.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Ribeiro C

Authors: Ribeiro C, Gomes F, Semedo M, Filipe F, Oliveira S,

Keywords: Neuroendocrine neoplasias, prognosis,